/CRDL
CRDL Stock - Cardiol Therapeutics Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$1.01+0.00%
+$0.00 (+0.00%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.27
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+692.1%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRDL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.00 – $1.02
TARGET (TP)$8.00
STOP LOSS$0.93
RISK/REWARD1:87.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.82
52W High$1.59
52W Low$0.77
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $62,267 | N/A |
| Gross Profit | N/A | $-187,383 | $-162,226 | $-111,997 | $-180,171 |
| Gross Margin | N/A | N/A | N/A | -179.9% | N/A |
| Operating Income | $-40,276,651 | $-22,473,162 | $-30,493,477 | $-30,568,391 | $-16,240,550 |
| Net Income | $-36,677,299 | $-21,222,796 | $-22,817,538 | $-25,013,195 | $-16,201,675 |
| Net Margin | N/A | N/A | N/A | -40170.9% | N/A |
| EPS | $-0.51 | $-0.44 | $-0.49 | $-0.73 | $-0.69 |
Company Overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 766.3% Upside
Now
$7
Low
$9
Average
$10
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 2nd 2025 | H.C. Wainwright | Initiation | Buy | $9 |
| January 28th 2025 | Rodman & Renshaw | Initiation | Buy | $7 |
| June 26th 2024 | ROTH MKM | Initiation | Buy | $10 |
| April 22nd 2024 | H.C. Wainwright | Initiation | Buy | $9 |
Earnings History & Surprises
CRDLBeat Rate
69%
Last 16 quarters
Avg Surprise
+2.2%
EPS vs Estimate
Beats / Misses
11/3
2 met exactly
Latest EPS
$-0.09
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.09vs$-0.09
Q2 24
-66.7%
$-0.10vs$-0.06
Q3 24
+30.0%
$-0.07vs$-0.10
Q4 24
-30.0%
$-0.13vs$-0.10
Q1 25
+12.5%
$-0.07vs$-0.08
Q2 25
+23.1%
$-0.10vs$-0.13
Q3 25
+36.4%
$-0.07vs$-0.11
Q4 25
0.0%
$-0.09vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.09 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.09 | $-0.09 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.11 | $-0.07 | +36.4% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.13 | $-0.10 | +23.1% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.10 | $-0.13 | -30.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.06 | $-0.10 | -66.7% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | $-0.09 | $-0.09 | 0.0% | = MET |
Q4 2023 | Nov 14, 2023 | $-0.12 | $-0.07 | +41.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.12 | $-0.09 | +25.0% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.15 | $-0.08 | +46.7% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $0.15 | $-0.09 | -160.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.10 | $-0.08 | +20.7% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q1 2022 | Mar 23, 2022 | $-0.11 | $-0.09 | +18.7% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | — | $-0.18 | — | — |
Q3 2021 | Aug 17, 2021 | — | $-0.13 | — | — |
Q2 2021 | May 18, 2021 | — | $-0.20 | — | — |
Latest News
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
📈 PositiveBenzinga•Dec 1, 2025, 06:07 PM
Cardiol Therapeutics Announces New, Comprehensive Data From ARCHER, Randomized Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Trial Of CardiolRx In Patients With Acute Myocarditis
📈 PositiveBenzinga•Dec 1, 2025, 12:32 PM
Cardiol Therapeutics Q3 EPS $(0.09), Inline
➖ NeutralBenzinga•Nov 13, 2025, 10:35 PM
Cardiol Therapeutics Receives USPTO Notice Of Allowance For Patent On Cannabidiol Heart Therapies
📈 PositiveBenzinga•Nov 13, 2025, 12:49 PM
Cardiol Therapeutics To Present New Data From ARCHER Trial, Highlighting Magnitude Of Reduction In LV Mass And Read Through To Heart Failure, At Cardiology Conference In November
📈 PositiveBenzinga•Oct 21, 2025, 11:30 AM
Trading Halt: Halt status updated at 5:00:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 17, 2025, 09:00 PM
Cardiol Therapeutics Completes $11M Private Placement Selling 11M Units At $1/Unit; Says MAVERIC Phase III Pivotal Trial Of Orphan Drug Candidate CardiolRx In Recurrent Pericarditis Is Fully Funded Through To A Planned NDA Submission With The FDA; Data From The ARCHER Trial To Be Presented At A Cardiology Conference In November 2025
📈 PositiveBenzinga•Oct 17, 2025, 08:38 PM
Trading Halt: Halted at 4:14:36 p.m. ET - Trading Halt: Halt News Pending
📉 NegativeBenzinga•Oct 17, 2025, 08:14 PM
Cardiol falls after mid-stage data for heart disease treatment
📉 NegativeSeeking Alpha•Aug 6, 2025, 01:56 PM
Frequently Asked Questions about CRDL
What is CRDL's current stock price?
Cardiol Therapeutics Inc. (CRDL) is currently trading at $1.01 per share. The stock has moved +0.00% today.
What is the analyst price target for CRDL?
The average analyst price target for CRDL is $8.00, based on 1 analyst.
What sector is Cardiol Therapeutics Inc. in?
Cardiol Therapeutics Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is CRDL's market cap?
Cardiol Therapeutics Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does CRDL pay dividends?
No, Cardiol Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASRT
Assertio Holdings, Inc.
$0.72
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
HYPR
Hyperfine, Inc.
$1.10
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
IMA
ImageneBio Inc
$6.18
Mkt Cap: $0.1B
INCR
InterCure Ltd.
$1.36
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
MBOT
Microbot Medical Inc.
$2.08
Mkt Cap: $0.1B
NSPR
InspireMD, Inc.
$1.99
Mkt Cap: $0.1B
VANI
Vivani Medical, Inc.
$1.39
Mkt Cap: $0.1B
Explore stocks similar to CRDL for comparison